馥感林口服液联合匹多莫德治疗儿童反复呼吸道感染疗效观察

Efficacy of fuganlin oral liquid and pidotimod in treatment of repeated respiratory tract infections in children

目的:探讨馥感林口服液联合匹多莫德治疗儿童反复呼吸道感染(RRTI)的疗效及不良反应。方法:将2012年8月—2014年2月儿科门诊就诊的RRTI患儿168例,随机分为观察组和对照A,对照B,对照C三组,每组各42例。对照A组给予馥感啉口服液,对照B组给予匹多莫德口服液,对照C组常规抗感染对症治疗,观察组给予馥感林口服液联合匹多莫德治疗。对各组患儿发热时间、临床症状进行比较并随访观察1年,对服药后1年内呼吸道感染发作次数进行统计学分析。结果:观察组热退、症状改善时间较对照B组及对照C组明显缩短(P<0.05)。停药后1年内呼吸道感染次数,观察组较对照A组及对照C组明显下降,差异有统计学意义(P<0.05)。结论:馥感啉口服液联合匹多莫德口服液治疗及预防反复呼吸道感染疗效确切,安全性较好。

Objective： To evaluate the efficacy and adverse reactions of fuganlin oral liquid and pidotimod in treatment of repeated respiratory tract infections（ RRTI） in children. Methods： All 168 patients with RRTI were randomly divided into observation group A（ 42 cases）,control Group A,B and C（ each 42 cases of group）. Group A were treated with fuganlin oral liquid,Group B were treated with pidotimod oral solution. Group C were treated with anti- infective and symptomatic treatment. The observation group were treated with fuganlin oral liquid and pidotimod. The fever time and clinical signs were observed. Within 1 year frequency of respiratory infection were statistically analyzed. Results： The time of back to normal body temperature,symptoms in observation group improved significantly shortened compared with control group B and C（ P〈0. 05）.The frequency of respiratory infection within 1 year,observation group decline significantly than the control group A and C（ P〈0. 05）. Conclusion： Fuganlin oral liquid and pidotimod is effective and safe in treatment of repeated respiratory tract infections in children.